^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BMS-986218

    i
    Other names: BMS-986218, CTLA-4-NF, BMS 986218
    Associations

    News

    Trials
    Company:
    BMS
    Drug class:
    CTLA4 inhibitor
    Related drugs:
    Associations

    News

    Trials
    4d
    Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies (clinicaltrials.gov)
    P1/2, N=13, Terminated, M.D. Anderson Cancer Center | Trial completion date: May 2027 --> Feb 2026 | Active, not recruiting --> Terminated | Trial primary completion date: May 2027 --> Feb 2026; <75% participation
    Trial completion date • Trial termination • Trial primary completion date
    |
    Opdivo (nivolumab) • BMS-986218
    8d
    Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial. (PubMed, Cell Rep Med)
    We present a neoadjuvant clinical trial testing whether an afucosylated anti-CTLA-4 antibody (BMS-986218) with ADT is safe, feasible, and reduces TI-Treg frequencies...Overall, this study supports the feasibility and biological activity of neoadjuvant ADT + Fc-enhanced anti-CTLA-4 in high-risk PCa. Trial is registered at clinicaltrials.gov (NCT04301414).
    P1 data • Journal
    |
    FCGR3A (Fc Fragment Of IgG Receptor IIIa)
    |
    BMS-986218
    7ms
    Neo-Red-P: Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer (clinicaltrials.gov)
    P1, N=26, Completed, Columbia University | Active, not recruiting --> Completed
    Trial completion
    |
    Firmagon (degarelix) • BMS-986218
    9ms
    A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=10, Terminated, Bristol-Myers Squibb | Completed --> Terminated; Business objectives have changed
    Trial termination
    |
    Opdivo (nivolumab) • docetaxel • BMS-986218
    9ms
    Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies (clinicaltrials.gov)
    P1/2, N=13, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: May 2025 --> May 2027 | Trial primary completion date: May 2025 --> May 2027
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • BMS-986218
    over1year
    Neoadjuvant androgen deprivation therapy with or without Fc-enhanced non-fucosylated anti-CTLA-4 (BMS-986218) in high risk localized prostate cancer: a randomized phase 1 trial. (PubMed, medRxiv)
    Patients receiving anti-CTLA4-NF also exhibited phenotypic signatures of enhanced antitumor T cell priming. In total, this study provides the first-in-human evidence of Treg depletion by glycoengineered antibodies targeting CTLA-4 in humans and their potential in combination with ADT in prostate cancer patients with high-risk of recurrence.
    P1 data • Journal
    |
    FCGR3A (Fc Fragment Of IgG Receptor IIIa)
    |
    BMS-986218
    over1year
    Neo-Red-P: Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer (clinicaltrials.gov)
    P1, N=26, Active, not recruiting, Columbia University | Trial primary completion date: Jun 2024 --> Jun 2025
    Trial primary completion date
    |
    Firmagon (degarelix) • BMS-986218
    almost2years
    Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies (clinicaltrials.gov)
    P1/2, N=13, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: May 2024 --> May 2025 | Trial primary completion date: May 2024 --> May 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • BMS-986218
    almost2years
    First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=512, Terminated, Bristol-Myers Squibb | N=390 --> 512 | Active, not recruiting --> Terminated; Business Objectives have changed.
    Enrollment change • Trial termination • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • BMS-986218
    2years
    First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=390, Active, not recruiting, Bristol-Myers Squibb | Trial primary completion date: Dec 2023 --> Apr 2024
    Trial primary completion date • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • BMS-986218
    2years
    A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=10, Completed, Bristol-Myers Squibb | Recruiting --> Completed | N=204 --> 10
    Trial completion • Enrollment change • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • docetaxel • BMS-986218
    over2years
    A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=204, Recruiting, Bristol-Myers Squibb | Trial completion date: Feb 2026 --> Dec 2023 | Trial primary completion date: Feb 2026 --> Dec 2023
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • docetaxel • BMS-986218